

From: [REDACTED]
Sent: Friday 15 January 2021 14:29
To: [REDACTED]
Cc: [REDACTED]
Subject: RE: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [REDACTED],

Thank you for the attached documents. We confirm that the re-submitted signed tender is sufficient.

As for point 2: **the Evidence that the** [REDACTED]

As for the files [REDACTED] – it is not necessary to resubmit updated Annexes as long as [REDACTED] in the requested evidence described above.

We remain at your disposal in case of further need of clarification.

Kind regards

[REDACTED]



European Commission
DG Health and Food Safety

[REDACTED]

From: [REDACTED] >
Sent: Wednesday, January 13, 2021 11:28 PM
To: [REDACTED] >
Cc: [REDACTED]
Subject: RE: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [REDACTED],

In response to your message from this morning – note the question highlighted in #2 & #3:

1. Thank you for your response – we are considering the [REDACTED] request by [REDACTED] fulfilled.

2. For the identified subcontractors: we would ask you to provide the Evidence that
- of the entity (see Section 4.3 of the Tender Specifications).

3. We would also ask you to resubmit the document "Novavax European Commission Tender - SANTE-2020-C3-087" [REDACTED]

Please see attached our full tender which includes

Regards,



21 Firstfield Road
Gaithersburg, MD 20878

Direct Line:

Mobile:

Email:

www.novavax.com

From:

Sent: Wednesday, January 13, 2021 9:06 AM

To:

Cc:

Subject: RE: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [REDACTED],

Please find below further clarifications and requests regarding your tender:

1. [REDACTED]
2. For the identified subcontractors: we would ask you to provide the Evidence that [REDACTED] of the entity (see Section 4.3 of the Tender Specifications). Please note that [REDACTED] the two documents are [REDACTED].
3. We would also ask you to resubmit the document "Novavax European Commission Tender - SANTE-2020-C3-087" [REDACTED] representative.

We remain at your disposal in case of any questions and doubts.

Kind regards

[REDACTED]



European Commission
DG Health and Food Safety

[REDACTED]

From: [REDACTED]
Sent: Monday, January 11, 2021 1:35 PM
To: [REDACTED]
Cc: [REDACTED]
Subject: RE: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Thank you for the response. We look forward to hearing back.
Regards,

[REDACTED]

From: [REDACTED]
Sent: Monday, January 11, 2021 3:10 AM
To: Frank Czworka <FCzworka@Novavax.com>
Cc: Kimberly Diaz <KDiaz@Novavax.com>; Jonathan Wallinger <jwallinger@Novavax.com>
Subject: RE: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

[REDACTED]

Dear [REDACTED],

We confirm the receipt of the documents, we will review them and come back to you with further requests if necessary.

Regarding your question about the additional financial documents, we need further consultation in that matter and we will come back to you with a clarification.

Kind regards

[Redacted]



European Commission
DG Health and Food Safety

[Redacted]

From: [Redacted]
Sent: Friday, January 8, 2021 4:21 PM
To: [Redacted]
Cc: [Redacted]
Subject: Fwd: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [Redacted],
Please see the following email with attachments as follow up to your recent request. We look forward to any updates.

Kind Regards,
[Redacted]
Novavax, INC.
Get [Outlook for iOS](#)

From: [Redacted] >
Sent: Friday, January 8, 2021 10:12 AM
To: [Redacted]
Cc: [Redacted]
Subject: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [Redacted]

In response to the additional information you requested on [Redacted], we are providing the following in hopes that it meets your needs:

1. [Redacted]
 1. [Redacted]

2a. Evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications

1. [Redacted]

2b. Evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:

2. [REDACTED]

Confidentiality Note

Please be advised that Novavax, Inc. (together with its subsidiaries "Novavax") is providing this proposal solely for the European Commission ("EC") to use in the call for tenders SANTE/2020/C3/087 - for the development, production, priority-purchasing options and supply of COVID-19 Vaccines for EU Member States (the "Project") and with the understanding that proposal contents will be treated as confidential. The information included in this proposal is confidential and/or private internal information of Novavax and its suppliers that is commercially sensitive and valuable. In accordance with the EC's procedures and relevant European Union law, we hereby request confidential treatment of all of the materials included in the proposal

Cheers,



NOVAVAX
Creating Tomorrow's Vaccines Today

22 Firstfield Road
Gaithersburg, MD 20878

Mobile: [REDACTED]

Email: [REDACTED]

www.novavax.com

From: [REDACTED]

Sent: Wednesday, January 6, 2021 10:41 AM

To: [REDACTED]

Cc: [REDACTED]

Subject: RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER



Dear [REDACTED],

After a first review of the documents submitted by Novavax Inc. it seems that we are missing the following elements:

1. Evidence regarding the financial and economic capacity [REDACTED] as described in **section 3.2.2. of the Tender Specifications.**
2. Evidence regarding the [REDACTED] as described in the section **VI of the** [REDACTED]
 1. **As evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications:** [REDACTED]
 2. **As evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:** [REDACTED]

Please note that this is a first, general review of your submission, and we might come back to you with further requests following the assessment by the evaluation committee.

We remain at your disposal in case of any doubts or questions regarding the request.

Kind regards

[REDACTED]



European Commission
DG Health and Food Safety

[REDACTED]